title: Rebuttal and response to: "The efficacy and tolerability issue of generics of imatinib in the treatment of chronic myeloid leukemia: do generics really jeopardize patient safety?" by Ahmet Emre Eskazan, Muhlis Cem Ar and Teoman Soysal.
authors.affiliation: The National Center of Hematology , Baghdad , Iraq.
authors.forename: Alaa Fadhil
authors.initials: AF
authors.lastname: Alwan
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy*; D008297:Male
chemical_list: D000970:Antineoplastic Agents